Completed PHASE3 INTERVENTIONAL NCT00180089

Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation

Sponsor: Dr. Falk Pharma GmbH

Conditions Graft-Versus-Host Disease Leukemia

Interventions Budesonide

Updated 5 times since 2017 Last updated: Mar 29, 2010 Started: Jan 31, 2004 Primary completion: Mar 31, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00180089, this PHASE3 trial focuses on Graft-Versus-Host Disease and Leukemia and remains completed. Sponsored by Dr. Falk Pharma GmbH, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Falk Pharma GmbH
Technische Universität Dresden

Data source: Technische Universität Dresden

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dresden, Germany